Analysis of orthodontic aligner biocompatibility: leachable compounds of different aligner materials正畸矫治器生物相容性分析:不同矫治器材料的可浸出化合物BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIKIF1.82025-09-010OA
A quantification of gastric and duodenal fluid volumes in older adults using MRIINTERNATIONAL JOURNAL OF PHARMACEUTICSIF5.22024-12-010PRE
Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic ExposurePHARMACEUTICSIF5.52023-05-021OAAI
Development of a Translational Exposure-Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug ProductsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-07-184OA
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenoneCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32021-11-2514OA
Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis ApproachCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-11-088PREAI
A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactionsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32021-05-2421OA
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic ModelingCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-12-1313OAAI
Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of MoxifloxacinCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32019-08-0717OAAI
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32019-03-1334OAAI
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and DigoxinCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32018-09-07132OAAI
Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication RegimensAAPS JOURNALIF3.72016-11-0737PREAI
Risk Assessment for Amikacin Inhale in Icu Patients Using Whole-Body Physiologically-Based Pk-ModelsCRITICAL CARE MEDICINEIF62013-12-010PREAI
Development of a physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in ratsFRONTIERS IN PHYSIOLOGYIF3.42013-01-0114OAAI
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networksFRONTIERS IN PHYSIOLOGYIF3.42011-01-01170OAAI